COVID: AstraZeneca drug neutralizes Omicron subvariants in study – CTV News

FOLLOW ON
Complete coverage at CTVNews.ca/Coronavirus
Receive the most important updates in your inbox
Track the number of people in Canada who have received doses
Advertisement
Reuters Staff
Contact
AstraZeneca said its antibody-based cocktail to prevent and treat COVID-19 was shown to retain neutralizing activity against Omicron coronavirus variants, including the highly contagious BA.2 subvariant, in an independent lab study.
Data from the study by the Washington University showed the therapy reduced the amount of virus detected in samples of all tested Omicron subvariants in mice lungs, the London-listed drugmaker said on Monday. The study has yet to be peer reviewed.
The therapy, Evusheld, was tested against the BA.1, BA.1.1, and BA.2 subvariants of Omicron and it was also shown to limit inflammation in the lungs.
"The findings further support Evusheld as a potential important option to help protect vulnerable patients such as the immunocompromised who could face poor outcomes if they were to become infected with COVID-19," senior AstraZeneca executive John Perez said.
The World Health Organization said last week figures showing a global rise in COVID-19 cases could herald a much bigger problem, as the Omicron and BA.2 variants spread amid the easing of restrictions and testing.
Vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, but Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.
The results come after Britain last week approved the therapy for preventing infections in adults with poor immune response. Evusheld is currently under a European review and has been authorized in the United States.
(Reporting by Pushkala Aripaka in Bengaluru; editing by Sriraj Kalluvila and Aditya Soni) 
Scott Madow, a heath services manager at a University of Washington medicine clinic, poses for a photo as he holds a box of AstraZeneca’s Evusheld on Jan. 20, 2022, in Seattle. (AP Photo/Ted S. Warren)
Tracking every case of COVID-19 in Canada
Coronavirus vaccination tracker: How many people in Canada have received shots?
When will feds lift COVID-19 mandates? It’s complicated, minister says
What could a new COVID-19 variant look like? Here’s what experts have to say
Ontario lifts mask mandates in most public spaces including schools, retail settings
Vaccine Hunters Canada winds down operations for a second time
Some children, teenagers retain natural COVID-19 antibodies for months: study
Canada’s international development minister urges WHO to approve Medicago vaccine
Federal government looking into removing some of its COVID-19 health measures: Tam
Bump in COVID-19 cases ‘not unexpected’ as public health measures lifted, Tam says
NACI recommends kids get Pfizer COVID-19 vaccine, calls Moderna suitable alternative
U.S. CDC reports fewer COVID-19 pediatric deaths after data correction
COVID-19 pandemic is ‘far from over’: WHO official
Coronavirus stats worldwide: Compare Canada and other key nations
Full coverage at CTVNews.ca/Coronavirus
Advertisement
Use of this Website assumes acceptance of Terms & Conditions and Privacy Policy.   Editorial Standards and Policies
© 2020All rights reserved.

source


0Shares

Add a Comment

Your email address will not be published.